To compare pathologic characteristics, treatment patterns and survival in patients with ductal adenocarcinoma (DC) compared to those with acinar adenocarcinoma (AC).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Using the National Cancer Database (NCDB), we identified patients diagnosed with clinically localized (cN0, cM0) pure DC (n=1,328) and AC (n=751,635) between 1998 and 2011.
High-risk AC was defined as Gleason 8-10 Demographic, treatment, pathological and survival characteristics of patients were compared
Compared to patients with Gleason 8-10 AC, those with DC presented with lower mean PSA (10 3 vs 16 2 ng/mL, p
In this large contemporary population-based series, patients with ductal adenocarcinoma of the prostate presented with lower PSA, had more favorable pathologic features, and similar overall survival compared to men with Gleason 8-10 AC
Urology 2015 Jul 18 [Epub ahead of print]
Vignesh T Packiam, Sanjay G Patel, Joseph J Pariser, Kyle A Richards, Adam B Weiner, Gladell P Paner, David J VanderWeele, Gregory P Zagaja, Scott E Eggener
Section of Urology, University of Chicago, Chicago, IL Electronic address: vignesh packiam@uchospitals edu , Section of Urology, University of Chicago, Chicago, IL , Section of Urology, University of Chicago, Chicago, IL , Department of Urology, University of Wisconsin-Madison, Madison, WI , Pritzker School of Medicine, The University of Chicago Medical Center, Chicago, IL , Department of Pathology, University of Chicago, Chicago, IL , Institute for Genomics and Systems Biology, Department of Medicine, University of Chicago, Chicago, IL , Section of Urology, University of Chicago, Chicago, IL , Section of Urology, University of Chicago, Chicago, IL